{ }
Very Negative
Negative
Neutral
Positive
Very Positive
2025-03-312025-03-31248866442200
Download SVG
Download PNG
Download CSV
Somewhat Relevant
Moderately Relevant
Very Relevant
Highly Relevant
2025-03-312025-03-3168866442200
Download SVG
Download PNG
Download CSV

wiss healthcare spending surpasses 100 billion francs amid rising costs

Swiss healthcare expenditure is projected to exceed CHF 100 billion in 2025, driven by an ageing population, population growth, and increased doctor visits. Health insurance premiums have surged by 8.7% this year and are expected to rise by another 6% next year, reflecting the escalating costs of healthcare.

ubs raises price target for swiss re to 150 francs maintains buy rating

UBS has upgraded its price target for Swiss Re from 136 to 150 francs while maintaining a "Buy" rating. Analyst Will Hardcastle anticipates a net income exceeding USD 4.5 billion in 2025, driven by an improved combined ratio and positive earnings momentum expected from the upcoming capital markets day in December.
16:57 18.11.2024

ubs raises price target for swiss re shares to 150 francs

UBS AG has upgraded its price target for Swiss Re shares from 136 to 150 francs, maintaining a "Buy" rating. Analyst Will Hardcastle anticipates a net income exceeding 4.5 billion USD in 2025, driven by improved combined ratios and positive earnings momentum expected from the upcoming capital markets day. As of midday trading, Swiss Re's share price rose 0.7% to CHF 123.20, reflecting a 30.3% increase since the start of 2024, with further growth potential of 21.75% to the new target.
12:37 18.11.2024

ubs raises price target for swiss re to 150 francs

UBS has increased its price target for Swiss Re from 136 to 150 francs while maintaining a "Buy" rating. Analyst Will Hardcastle anticipates net income exceeding USD 4.5 billion in 2025, citing an improved combined ratio and positive earnings momentum expected from the upcoming Capital Markets Day in mid-December.
11:46 18.11.2024

ubs raises price target for swiss re to 150 francs

UBS has increased its price target for Swiss Re from 136 to 150 francs, maintaining a "Buy" rating. Analyst Will Hardcastle anticipates a net income exceeding USD 4.5 billion in 2025, citing an improved combined ratio and positive earnings momentum expected from the upcoming Capital Markets Day in mid-December.
11:46 18.11.2024

Swiss market remains directionless as pharmaceutical stocks face pressure

Swiss stocks are experiencing a lack of direction, with Lonza, Richemont, Swiss Re, and Nestlé seeing increased demand. In Japan, share prices are pressured by the appointment of an anti-vaccination campaigner to a key health position, significantly impacting pharmaceutical stocks, particularly Chugai Pharmaceutical, which dropped 8.56%. Equity strategist Kazuo Kamitani suggests ongoing market turbulence, exacerbated by a strong yen affecting export-oriented carmakers.
06:09 18.11.2024

swiss stock market faces downturn amid us interest rate concerns

The Swiss stock market remains in a bearish trend, with the SMI Guiding Values Index down 1.08% to 8174.97 points, influenced by concerns over potential U.S. interest rate hikes. Major banks like UBS and Credit Suisse faced significant losses, while defensive stocks like Nestlé and Novartis attempted to mitigate the downturn. Kudelski saw a positive turn with a court victory against China's Gotech, while Adienne announced plans to enter the stock market without further details.
18:34 15.11.2024

swiss stock exchange declines as investors react to us interest rate concerns

The Swiss stock exchange closed lower, with the SMI down 0.70% at 8206.20 points, following concerns over potential U.S. interest rate hikes. Major banks like UBS and Credit Suisse faced significant losses, while defensive stocks like Nestlé and Novartis attempted to mitigate the downturn. Market experts anticipate a turbulent period ahead after recent volatility in U.S. markets.
17:32 15.11.2024

ubs maintains buy rating for swiss re with target price of 136 francs

UBS AG has maintained a "Buy" rating for Swiss Re, setting a target price of 136 francs following the third quarter results, with expectations for increased profit forecasts in 2025. Despite a 1.9% drop in share price to CHF 118.30, there remains a potential upside of 14.96%. The share has risen 25.1% since the start of 2024, with Q3 2024 financial figures set to be released on November 14, 2024.
10:19 14.11.2024

swiss re reports lower profits due to increased reserves and major losses

Swiss Re reported a profit of $100 million in Q3 2024, significantly impacted by a $2.4 billion increase in reserves for past-year claims, particularly in the U.S. liability business. The Property & Casualty Re division's profit fell to $603 million, while the Life & Health Re division performed better with a profit of $1.2 billion. Looking ahead, the group expects to exceed $3 billion in profit for the year, despite anticipated losses from Hurricane Milton.
Trending
Subcategory
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.